Holen Sie sich die Stockscreener-App
1.45
2.03%
-0.03
Handel nachbörslich:
1.45
Schlusskurs vom Vortag:
$1.48
Offen:
$1.49
24-Stunden-Volumen:
72,462
Relative Volume:
0.02
Marktkapitalisierung:
$5.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.22M
KGV:
-0.053
EPS:
-27.3467
Netto-Cashflow:
$-8.01M
1W Leistung:
+5.07%
1M Leistung:
-19.44%
6M Leistung:
-65.06%
1J Leistung:
-90.49%
1-Tages-Spanne:
$1.42
$1.49
1-Wochen-Bereich:
$1.38
$1.5794
52-Wochen-Spanne:
$1.26
$17.64
Enveric Biosciences Inc Stock (ENVB) Company Profile
Firmenname
Enveric Biosciences Inc
Sektor
Branche
Telefon
(617) 444-8400
Adresse
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.45 | 5.96M | 0 | -8.22M | -8.01M | -27.35 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enveric Biosciences Inc Aktie (ENVB) Neueste Nachrichten
Enveric Biosciences to Participate in B. Riley's Mind, Muscle & Vision Summit - GuruFocus
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - Business Wire
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Stocktwits
ENVBEnveric Biosciences Inc Earnings - Finviz
Enveric Biosciences Company Profile & Introduction - Moomoo
Enveric Biosciences, Inc. Actuals & Estimates (NASDAQ:ENVB) - TradingView
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits
Enveric Biosciences Inc (ENVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enveric Biosciences Inc (ENVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enveric Biosciences Inc (ENVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enveric Biosciences Inc (ENVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ENVERIC BIOSCIENCES INC (ENVB) Stock Chart - ChartMill
Enveric Biosciences Inc (ENVB) Institutional Confidence - TradingKey
Enveric Biosciences Inc (ENVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enveric Biosciences Inc (ENVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enveric Biosciences Inc (ENVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enveric Biosciences Inc (ENVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enveric Biosciences Announces Participation in 2026 BIO International Convention - Investing News Network
Enveric Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
ENVB SEC FilingsEnveric Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enveric Biosciences Expands At-The-Market Equity Offering - TipRanks
Enveric Biosciences (NASDAQ: ENVB) expands $2.4M at-the-market stock program - Stock Titan
Enveric Biosciences (ENVB) amends ATM; $2.425M remaining capacity - Stock Titan
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day - Investing News Network
Enveric Biosciences Releases Updated Investor Presentation Materials - TipRanks
Enveric Biosciences posts investor presentation on website under Regulation FD - TradingView
Enveric Biosciences (NASDAQ: ENVB) furnishes Q2 2026 investor presentation - Stock Titan
ENVB News | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
[Form 4] Enveric Biosciences, Inc. Insider Trading Activity - Stock Titan
Enveric Biosciences (ENVB) CFO awarded 133,333 RSUs in long-term equity grant - Stock Titan
Enveric Biosciences (ENVB) CEO granted 201,124 RSUs under 2020 long-term plan - Stock Titan
Enveric Biosciences (ENVB) director receives 18,518 restricted stock shares as equity grant - Stock Titan
Director at Enveric Biosciences (ENVB) receives 18,518 restricted shares - Stock Titan
Enveric (ENVB) awards director Marcus Schabacker 18,518 restricted shares - Stock Titan
Enveric Biosciences (ENVB) awards 25,000 RSUs to its CIO - Stock Titan
Enveric Biosciences (ENVB) Launches Critical Safety Studies for EB-003 - GuruFocus
Enveric Biosciences Initiates Investigational New Drug -enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences stock rises on genotoxicity study launch By Investing.com - Investing.com India
Enveric Biosciences stock rises on genotoxicity study launch - Investing.com
Enveric Biosciences begins genotoxicity studies for EB-003 - Investing.com
Enveric Biosciences begins genotoxicity studies for EB-003 By Investing.com - Investing.com Canada
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Business Wire
Enveric Biosciences (NASDAQ: ENVB) holders OK reverse split, block share increase - Stock Titan
Enveric Biosciences Holds Near Support Amid Modest PullbackPCR Moving Average - thelegaladvocate.com
Enveric Biosciences (ENVB) Narrows as Support Zone Holds FirmLate Stage Breakouts - dars.gov.et
ENVB Stock Price, Quote & Chart | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Inc. (ENVB) Q4 2024 Earnings: Massive EPS Miss Highlights Ongoing Cash Burn and No Revenue - thelegaladvocate.com
Enveric Biosciences (ENVB) Achieves Key Milestone in Neuropsychi - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 - Investing News Network
Finanzdaten der Enveric Biosciences Inc-Aktie (ENVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):